NASDAQ: DOMHDominari Holdings Inc Stock
$6.07+0.14 (+2.36%)
Updated Sep 16, 2025
DOMH Price
$6.07
Fair Value Price
N/A
Market Cap
$92.98M
52 Week Low
$0.83
52 Week High
$13.58
P/E
-2.55x
P/B
1.06x
P/S
1.53x
PEG
N/A
Dividend Yield
8.9%
Revenue
$52.81M
Earnings
-$19.02M
Gross Margin
100%
Operating Margin
-36.01%
Profit Margin
-36%
Debt to Equity
0.24
Operating Cash Flow
-$7M
Beta
1.2
Next Earnings
Nov 14, 2025
Ex-Dividend
Sep 3, 2025
Next Dividend
Sep 26, 2025
DOMH Overview
Dominari Holdings Inc., a U.S.-based capital markets firm offering wealth management, investment banking, sales & trading, and asset & portfolio management. It operates through segments like Dominari Financial and Legacy AIkido.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DOMH's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DOMH
Ranked#30 of 479
Ranked#30 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.87 | A | |
| $34.98 | A | |
| $7.75 | A |
Be the first to know about important DOMH news, forecast changes, insider trades & much more!
DOMH News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DOMH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DOMH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DOMH is good value based on its book value relative to its share price (1.06x), compared to the US Biotechnology industry average (4.68x)
P/B vs Industry Valuation
DOMH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more DOMH due diligence checks available for Premium users.
Valuation
DOMH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.55x
Industry
-95.43x
Market
37.55x
DOMH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.06x
Industry
4.68x
DOMH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DOMH's financial health
Profit margin
Revenue
$34.1M
Net Income
$16.6M
Profit Margin
48.7%
DOMH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DOMH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$109.3M
Liabilities
$20.7M
Debt to equity
0.24
DOMH's short-term assets ($60.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DOMH's short-term assets ($60.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DOMH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DOMH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$353.0k
Investing
$1.2M
Financing
$2.3M
DOMH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DOMH vs Biotech Stocks
Dominari Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.